Brand Awareness Archives - Page 6 of 41

TuesdayNov 19, 2024 9:00 am

Key Metals Surge, Unlocking New Opportunities for Savvy Mining Investors

NetworkNewsWire Editorial Coverage: Investment interest in the mining space is growing, driven by increasing demand for a wide range of metals that are becoming essential to modern industries. The push for clean-energy technologies, such as electric vehicles (“EVs”) and renewable energy systems, has amplified the need for critical minerals such as lithium, cobalt, nickel and rare earth elements. Meanwhile, traditional metals such as copper and aluminum are experiencing a resurgence due to their critical role in infrastructure and energy transmission. Gold and silver, as traditional stores of value, remain attractive amid economic uncertainties and inflationary pressures. Finally, the global transition…

ThursdayOct 03, 2024 9:00 am

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More

NetworkNewsWire Editorial Coverage: Pharmaceutical companies are demonstrating innovation by not only developing new drugs but also exploring combination therapies and repurposing existing drugs to address unmet medical needs. This strategic approach holds promise for providing hope to millions of patients suffering from historically challenging diseases. Alzheimer's disease (“AD”) for example, has become a focal point of this innovation, with recent U.S. Food and Drug Administration (“FDA”) approvals of Leqembi and Kisunla — although these treatments only slow cognitive decline rather than improve cognitive function. New uses for approved glucagon-like peptide-1 (“GLP-1”) and phosphodiesterase 5 (“PDE5”) inhibitor drugs show promise in…

TuesdayOct 01, 2024 9:00 am

Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition

NetworkNewsWire Editorial Coverage: Alzheimer’s disease (“AD”) has become a focal point in the pharmaceutical industry as recent drugs such as Leqembi and Kisunla have received U.S. Food and Drug Administration (“FDA”) approval. However, while these treatments may slow cognitive decline in AD patients, they do not actually improve cognition, a critical target for the millions suffering from the progressive disease. In addition, GLP-1 (glucagon-like peptide-1) drugs, which were originally developed to manage type 2 diabetes and since have seen significant effectiveness in treating obesity, have also shown potential in the treatment of Alzheimer's. However, there is no molecule or a…

WednesdayFeb 14, 2024 9:00 am

The Electrifying Rise of Electric Boats

NetworkNewsWire Editorial Coverage: The raucous rumble of combustion engines is fading, systematically replaced by the high-performance hum of electric propulsion that’s transforming every aspect of transport. Electric cars have moved mainstream with both automakers and upstarts offering multiple mobility options. Now another market is being disrupted, as sleek electric boats glide across the water leaving nothing but a whisper of ripples in their wake. This surge in electrification isn't just about a clean and green conscience; it's about performance, convenience and a technological transition in mobility that may be as profound as the shift from the horse to the horseless carriage.…

WednesdayJan 10, 2024 9:00 am

GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons

NetworkNewsWire Editorial Coverage: On Sept. 20, 2019, history was made when the U.S. Food and Drug Administration approved Rybelsus as the first oral glucagon-like peptide-1 (GLP-1) agonist for type 2 diabetes (T2D). However, it wasn't just a milestone for T2D management. It was a turning point in medicine, opening the floodgates to a universe of potential therapeutic applications for this remarkable molecule. While undeniably transformative for diabetes and weight loss, GLP-1's reach now extends far beyond, likely surpassing even the wildest dreams of its creators. From Alzheimer's and Parkinson's to drug addiction, clinical trials are painting a stunning picture of GLP-1's…

MondayJan 08, 2024 9:00 am

Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs

NetworkNewsWire Editorial Coverage: Already proven to be a revolutionary treatment for type 2 diabetes and weight loss, glucagon-like peptide-1 (GLP-1) agonists now appear to have a multitude of potential blockbuster therapeutic uses, according to recent research. Obviously, diabetes remains a primary indication, given the massive global need. However, the impact of this extraordinary molecule extends far beyond type 2 diabetes. The reach of GLP-1 drugs has widened in ways its inventors likely never imagined. Clinical trials are underway testing GLP-1 drugs to treat Alzheimer’s, Parkinson’s, and even drug addiction, plus there are strong indications of therapeutic efficacy in heart disease and…

WednesdayNov 01, 2023 9:00 am

Get Ready for Next Generation of Diabetes, Weight-Management Drugs

NetworkNewsWire Editorial Coverage: GLP-1 agonists have become incredibly popular obesity drugs, reshaping the standard of care as people increasingly turn to the new class of drugs in lieu of conventional weight-loss procedures. There is a growing body of clinical evidence showing GLP-1 agonists safely control blood sugar (glucose) levels and deliver tremendous positive outcomes, such as a recent New England Journal of Medicine study reporting weight loss of 49 to 52 pounds. As good as GLP-1 agonist are, they can get better, which is part of the mission of Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile), a global innovator in drug-delivery platforms.…

MondayOct 30, 2023 9:00 am

Can Diabetes, Weight-Loss Drugs Get Even Better?

NetworkNewsWire Editorial Coverage: The prestigious New England Journal of Medicine recently published results of a large study of 2,539 adults wherein weight loss of 49 to 52 pounds was a common outcome. With more than 37 million Americans suffering from diabetes, and with obesity at epidemic levels, it’s little wonder that millions of people are singing their praises of the new class of drugs responsible for these outrageously positive outcomes. GLP-1 agonists are a class of medications that mainly help manage blood sugar (glucose) levels in people with type 2 diabetes but are also helping treat obesity. Seems everyone is excited…

ThursdayOct 12, 2023 9:00 am

Volatile Economy Makes Gold Space ‘Increasingly Attractive’

NetworkNewsWire Editorial Coverage: In uncertain economic times, stability is a rare commodity. Historically, one of the most stable spaces during fragile economies is gold, a highly liquid asset that carries no credit risk and preserves its value over time. The precious metal also benefits from diverse sources of demand: as an investment, a reserve asset, gold jewelry, or a technology component. These attributes mean gold can enhance a portfolio in three ways: delivering long-term returns, improving diversification and providing liquidity. Many gold mining companies, including GEMXX Corp. (OTC: GEMZ) (Profile), are seeing significant growth and success during the recent volatile economy. Quickly graduating past…

TuesdayOct 10, 2023 9:00 am

Safety, Stability and Upside in Uncertain Times

NetworkNewsWire Editorial Coverage: In volatile economic conditions, smart money seeks stability and moves to safe havens. Historically, one of the safest places and most stable spaces during economic uncertainty is gold, a highly liquid asset that preserves and even increases in value over time and carries no credit risk. The precious metal benefits from multiple levers of demand such as gold jewelry, tech/industrial use and a reserve asset as well as a strategic investment. History has shown that gold’s variable demand pressures enhance a portfolio by improving diversification, providing liquidity and delivering long-term returns. Reacting to uncertainties, many gold mining companies, including…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

Category: Brand Awareness